Document is current
Any future updates will be listed below
-
Authors
Wu, Li-Tzy http://orcid.org/0000-0002-5909-2259
John, William S.
Mannelli, Paolo
Morse, Eric D.
Anderson, Alyssa
Schwartz, Robert P.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (U01DA046910-02S3)
- License Information
-
More Information
Article History
Received: 7 November 2022
Accepted: 24 July 2023
First Online: 2 August 2023
Declarations
:
: This interview study was approved by the Duke University Health System Institutional Review Board. The parent study’s ClinicalTrials.gov Identifier is NCT04308694.
: Not applicable.
: Dr. Mannelli has consulted for Alkermes, Intracellular Therapies, Indivior, and Guidepoint Global. Dr. Schwartz has consulted for Verily Life Sciences. He was Principal Investigator of a NIDA-funded study that has received medication at no cost to the study from Alkermes and Indivior. The other authors have no conflicts of interest to disclose.
